HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orally Dissolving Competition Lurks For Prevacid 24HR, Other OTC PPIs

This article was originally published in The Pink Sheet

Executive Summary

While GSK Consumer Healthcare's latest ad campaign for Prevacid 24HR features "Lurker," a fireball character who educates consumers on the risk of recurrence of heartburn, oral disintegration of an active ingredient is the latest differentiator in the OTC PPI category.

You may also be interested in...



New Parent Lonza Welcomes Capsugel's Independent Streak To Innovate

Lonza acquires Capsugel for $5.5bn cash, nearly twice as much as private equity firm KKR paid Pfizer for it, to enhance its product development and expand the market for its contract development and manufacturing services for drug and nutritional products.

User-Friendly OTC Dosage Forms Deliver Opportunity For Industry

Hermes Pharma executive Thomas Hein recommends the OTC industry consider formulating APIs in user-friendly dosage forms, rather than in traditional tablets and capsules, to provide consumers with ease-of-swallowing and additional lifestyle convenience. Charts detail consumer preferences based on recent survey.

Sanofi Adds Consumer Brands, Grows Footprint With Boehringer Ingelheim Deal

BI international brands including Mucoangin cough suppressant and Dulcolax constipation treatment and US heartburn remedy Zantac would join Sanofi's consumer portfolio including US brands Allegra Allergy antihistamines and Nasacort Allergy 24HR nasal decongestant in the firm's proposed asset swap.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel